Browsing Sentraladministrasjonen by Journals "Journal of Cachexia, Sarcopenia and Muscle"

Now showing items 1-2 of 2

    • Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series 

      Yule, Michael S.; Thompson, Joshua; Leesahatsawat, Khachonphat; Sousa, Mariana S.; Anker, Stefan D.; Arends, Jann; Balstad, Trude Rakel; Brown, Leo R.; Bye, Asta; Dajani, Olav; Fallon, Marie; Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; McDonald, James; McGovern, Josh; Roeland, Eric J.; Sayers, Judith; Skipworth, Richard J.E.; Ottestad, Inger; Philips, Iain; Simpson, Melanie Rae; Solheim, Tora S; Vagnildhaug, Ola Magne; McMillan, Donald; Laird, Barry J; Dolan, Ross D. (Peer reviewed; Journal article, 2024)
      Regulatory agencies require evidence that endpoints correlate with clinical benefit before they can be used to approve drugs. Biomarkers are often considered surrogate endpoints. In cancer cachexia trials, the measurement ...

    • Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series 

      McDonald, James; Sayers, Judith; Anker, Stefan D.; Arends, Jann; Balstad, Trude Rakel; Baracos, Vickie; Brown, Leo; Bye, Asta; Dajani, Olav; Dolan, Ross; Fallon, Marie T.; Fraser, Eilidh; Griel, Christine; Grzyb, Aleksandra; Hjermstad, Marianne Jensen; Jamal-Hanjani, Mariam; Jakobsen, Gunnhild; Kaasa, Stein; McMillan, Donald; Maddocks, Matthew; Philips, Iain; Ottestad, Inger; Reid, Kieran F.; Sousa, Mariana S.; Simpson, Melanie Rae; Vagnildhaug, Ola Magne; Skipworth, Richard J. E.; Solheim, Tora S; Laird, Barry J (Peer reviewed; Journal article, 2023)
      In cancer cachexia trials, measures of physical function are commonly used as endpoints. For drug trials to obtain regulatory approval, efficacy in physical function endpoints may be needed alongside other measures. However, ...